Leerink Partners Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price

Amgen (NASDAQ:AMGN) had its price objective upped by stock analysts at Leerink Partners from $395.00 to $464.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “market perform” rating on the medical research company’s stock. Leerink Partners‘s price target would suggest a potential upside of 0.81% from the company’s previous close.

Other research analysts have also issued research reports about the stock. HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and decreased their target price for the stock from $445.00 to $425.00 in a research report on Thursday, September 10th. Barclays lifted their price target on shares of Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 21st. The Goldman Sachs Group boosted their price target on Amgen from $481.00 to $536.00 and gave the company a “buy” rating in a research note on Wednesday. Sanford C. Bernstein raised their price objective on Amgen from $345.00 to $400.00 and gave the stock a “market perform” rating in a research note on Wednesday. Finally, Wells Fargo & Company raised their price objective on Amgen from $430.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, seventeen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $419.10.

Amgen Stock Performance

Amgen stock traded down $18.20 during trading hours on Thursday, hitting $460.28. The company had a trading volume of 4,018,726 shares, compared to its average volume of 2,758,203. The firm has a market cap of $248.84 billion, a PE ratio of 26.70, a PEG ratio of 3.38 and a beta of 0.43. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen has a one year low of $312.39 and a one year high of $483.99. The firm has a 50-day moving average of $421.56 and a 200 day moving average of $376.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a return on equity of 128.15% and a net margin of 24.14%. The business’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.64 earnings per share. On average, sell-side analysts expect that Amgen will post 22.96 earnings per share for the current year.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amgen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares in the last quarter. State Street Corp increased its stake in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Amgen by 12.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after purchasing an additional 605,928 shares in the last quarter. Bank of America Corp DE bought a new stake in Amgen during the second quarter worth approximately $1,831,903,000. Finally, Amundi lifted its position in Amgen by 15.2% in the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock worth $1,408,715,000 after purchasing an additional 512,883 shares during the period. 76.50% of the stock is owned by institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: A real-world study of more than 500,000 people with heart disease found Repatha was associated with a 20% lower risk of fatal or nonfatal heart attacks than ezetimibe. The findings could strengthen the drug’s case in non-statin treatment decisions. Repatha study
• Positive Sentiment: Amgen reported Q3 revenue of $10.37 billion, up 8.5% year over year, and adjusted EPS of $6.45, beating estimates. It also raised its 2026 outlook, supported by growth products including Repatha and Imdelltra. Q3 results
• Neutral Sentiment: The company announced a collaboration with the National Organization for Rare Disorders to help speed diagnosis of selected rare autoimmune diseases, while also highlighting AI-assisted RNA drug discovery. These initiatives may support longer-term pipeline growth, but are not near-term revenue drivers. Rare disease and RNA initiatives
• Negative Sentiment: Guggenheim raised its price target to $435 but kept a neutral rating, putting its estimate below the current share level. The stock’s retreat may also reflect concerns that biosimilar competition is pressuring Prolia and Xgeva, despite growth elsewhere in the portfolio. Biosimilar pressure and earnings context

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.